Despite recent significant advances in the treatment of hematological malignancies, relapse of this disease is of great note with the existence of the minimal residual disease (MRD). Tumour peptide vaccine seems to be one of the effective immunotherapies for eliminating tumor cells of MRD. This review focuses on the late results of clinical trails of peptide vaccination protocols targeting WT1, RHAMM, BCR-ABL, PR1 in hematological malignancies and the development of specific immune responses to PRAME and Survivin peptides. An outlook to heteroclitic peptides, new adjuvants, combined peptide vaccines and Ad-tWT1 vaccine is also given to further explore the possibility to enhance the efficacy of the peptide vaccine.
Adjuvants, Immunologic ; Cancer Vaccines ; immunology ; Hematologic Neoplasms ; immunology ; therapy ; Humans ; Vaccines, Subunit ; immunology

As the most potent antigen-presenting cells (APC), dendritic cells are important in launching both humoral and cellular immune responses against tumor. Although the high evaluation of DC in immunotherapy for cancer by means of DC vaccines, more studies have indicated DC is a heterogeneous population and proved that DC subsets are prominent determinants for the effectiveness of immune responses. Different DC subsets display different receptors and surface molecules, and express different sets of cytokines/chemokines, which result in distinct immunological outcomes. Clinical trials with ex vivo generated DC vaccines also manifest unexpected immunological tolerance as well as allergic response. It is essential to study the biological aspects of human DC subsets, which may be a key to the generation of novel DC-based vaccines. In this article, the progress of studies on biology of dendritic cells including their origins, differentiation, function and application of DC subsets is reviewed.
Cancer Vaccines ; therapeutic use ; Dendritic Cells ; immunology ; Humans ; Neoplasms ; therapy

Tumor antigen-specific cytotoxic T lymphocytes are important anti-cancer cells. The focuses of this review are to introduce the molecular basis of antigen presentation and CTL recognition, to summarize the identification of tumor associated antigens and their T cell epitopes, to highlight the current insights into the immunogenicity of TAA peptides and the principles of peptide-based vaccines against cancer, and to comment on future prospects for CTL therapy.
Animals ; Antigens, Neoplasm ; immunology ; Cancer Vaccines ; immunology ; Humans ; Immunotherapy ; Neoplasms ; immunology ; therapy ; T-Lymphocytes, Cytotoxic ; immunology

Antigens, Neoplasm ; immunology ; Cancer Vaccines ; immunology ; Carcinoma, Hepatocellular ; immunology ; therapy ; Humans ; Immunotherapy ; Liver Neoplasms ; immunology ; therapy

The study of tumor vaccine is one of the focus of immunological therapy on malignant gynecologic cancer. All of the ovarian carcinoma vaccine are therapeutic, including cloned antigen vaccine, tumor cell vaccine, genetic engineering tumor cell vaccine, dendritic cell (DC) vaccine, as well as anti-idiotypic vaccine. The therapeutic vaccines based on human papillomavirus (HPV) of cervical cancer are mostly summarized, including polypeptides vaccine, carrier vaccine, fusion protein or chimeric vaccine, and DC vaccine. The preventive vaccine based on HPV of cervical cancer are briefly introduced. As there are only a few reports on endometrial carcinoma vaccine.
Cancer Vaccines ; biosynthesis ; immunology ; Dendritic Cells ; immunology ; Female ; Genetic Engineering ; Humans ; Ovarian Neoplasms ; immunology ; Papillomaviridae ; immunology ; Papillomavirus Infections ; immunology ; Uterine Cervical Neoplasms ; immunology ; Vaccines, DNA ; immunology

To investigate the specific anti-leukemia effect of cytotoxic T lymphocytes (CTLs) induced by dendritic cells (DCs) activated by exosomes alone or in combination with CpG ODN in vitro and the feasibility of exosomes as remedial vaccine, the DCs induced from normal volunteer PBMNCs were divided into 7 groups. Three groups of them were added with the exosomes: Kexo (exosomes derived from K562 cells) or DCexo (exosomes derived from DCs induced from K562 cells) or FTexo (exosomes derived from DCs induced from K562 cells and pulsed by freeze-thawing antigen of K562 cells) as experimental groups (Kexo, DCexo and FTexo). The other three groups were added with CPG ODN while added the exosomes (Kexo, DCexo and FTexo), and were used as experimental groups also (Kexo+CpG, DCexo+CpG and FTexo+CpG). The seventh group DCs was added with nothing as blank control. These DCs above mentioned were cultured continuously for 72 hours. The T lymphocytes were co-cultured with DCs for another 72 hours to generate CTL. Then, the killing effects of them on K562 cells were determined by MTT assay. The results showed that all experimental groups pulsed by exosomes displayed stronger killing effect, compared with control group (p<0.05). DCexo and FTexo displayed stronger killing effect too, compared with Kexo (p<0.05). CPG ODN as an adjuvant could enhance the killing effect (p<0.05). It is concluded that the special killing effect on K562 cells can be induced by exosomes, CPG ODN as an adjuvant can enhance the killing effect. Exosome is hopeful as a remedial vaccine to be used for the leukemia therapy.
Adjuvants, Immunologic ; pharmacology ; Cancer Vaccines ; immunology ; Dendritic Cells ; immunology ; Exosomes ; immunology ; Humans ; K562 Cells ; Oligodeoxyribonucleotides ; immunology ; T-Lymphocytes, Cytotoxic ; immunology

As the potent professional antigen present cell, dendritic cells (DC) play an important role in the initiation for anti-tumor immunity. Prostate cancer (PCa) can reduce the number and function of tumor infiltrated dendritic cells (TIDC) by a series of complicated mechanisms, escaping from immunosurveillance. With the development of immunology, more and more studies focus on TIDC and DC-based vaccines for PCa. However, all these studies are still at the exploratory stage. Here is a review of the related literature.
Cancer Vaccines ; therapeutic use ; Dendritic Cells ; cytology ; immunology ; Humans ; Immunotherapy ; Male ; Prostatic Neoplasms ; immunology ; therapy

Patients with multiple myeloma (MM) have increased constantly in recent years, but treatment for patients with MM is currently unsatisfactory and it is necessary to develop new complementary therapies. Dendritic cells (DCs) are specialized antigen-presenting cells capable of initiating and regulating immune responses. Vaccination with tumor antigen-pulsed DCs has shown to be safe and possesses therapeutic effect against many tumors. In this review, the various types of MM-associated antigens and clinical trials on DC-based immunotherapy in MM are summarized, the development of DC immunotherapy for MM patients in future trials is discussed.
Cancer Vaccines ; immunology ; therapeutic use ; Dendritic Cells ; immunology ; Humans ; Immunotherapy ; Multiple Myeloma ; therapy

Dendritic cell (DC), the most powerful antigen presenting cell, has been paid close attention to tumor immunotherapy. The tumor antigens were extracted by different ways to pulse DC, and then the mature DC were infused to patients to accelerate anti-tumor immuno responses. Its clinical use would provide a new therapeutic pathway other than surgical operation, irradiation, chemotherapy. In this paper, biological characteristics of DC, tumor-vaccine preparation and its clinical use were reviewed.
Cancer Vaccines ; immunology ; Cell Culture Techniques ; Dendritic Cells ; immunology ; Humans ; Neoplasms ; therapy

Antigens, Neoplasm ; immunology ; Cancer Vaccines ; therapeutic use ; Dendritic Cells ; immunology ; Humans ; Immunotherapy ; methods ; Liver Neoplasms ; therapy